Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice

Leukemia

Volumn 29, Issue 4, 2015, Pages 947-957

  Deligne, C ^a,b,c   Metidji, A ^a,c,d   Fridman, W H ^a,b,c   Teillaud, J L ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 12; ANTINEOPLASTIC AGENT; CD4 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; MONOCLONAL ANTIBODY; RITUXIMAB;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; LONG TERM SURVIVAL; LYMPH NODE; LYMPHOCYTE COUNT; MEMORY T LYMPHOCYTE; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR IMMUNITY; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOMA, B-CELL; MORTALITY; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD4; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, LEUKEMIC; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-12; LYMPH NODES; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 84927674425     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.275     Document Type: Article

References (39)

1. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
3. Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010; 47: 107-114.
4. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-446.
5. Sibéril S, Dutertre CA, Fridman WH, Teillaud JL. FcgammaR: The key to optimize therapeutic antibodies? Crit Rev Oncol Hematol 2007; 62: 26-33.
6. De Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol 2008; 140: 635-643.
7. Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115: 4393-4402.
8. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: Ways to improve rituximab efficacy. Blood 2004; 104: 2635-2642.
9. Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F et al. Rituximab immunotherapy results in the induction of a lymphoma idiotypespecific T-cell response in patients with follicular lymphoma: Support for a ?vaccinal effect' of rituximab. Blood 2009; 113: 3809-3812.
10. Abès R, Gélizé E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010; 116: 926-934.
11. Abès R, Teillaud JL. Modulation of tumor immunity by therapeutic monoclonal antibodies. Cancer Metastasis Rev 2011; 30: 111-124.
12. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-1701.
13. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.
14. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18: 160-170.
15. Mortenson ED, Park S, Jiang Z, Wang S, Fu YX. Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. Clin Cancer Res 2013; 19: 1476-1486.
16. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 2011; 108: 7142-7147.
17. Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y et al. Targeting the tumor microenvironment with interferon-? bridges innate and adaptive immune responses. Cancer Cell 2014; 25: 37-48.
18. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450: 903-907.
19. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010; 127: 759-767.
20. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
21. Brody JD, Goldstein MJ, Czerwinski DK, Levy R. Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood 2009; 113: 85-94.
22. Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009; 114: 3431-3438.
23. Nasser R, Pelegrin M, Plays M, Gros L, Piechaczyk M. Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies. Blood 2013; 121: 1102-1111.
24. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146.
25. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177: 1199-1204.
26. Borg C, Jalil A, Laderach D, Maruyama K, Wakasugi H, Charrier S et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 2004; 104: 3267-3275.
27. Lee SC, Srivastava RM, López-Albaitero A, Ferrone S, Ferris RL. Natural killer (NK): Dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res 2011; 50: 248-254.
28. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306.
29. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun 2012; 12: 14.
30. Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell 2012; 148: 1081-1084.
31. Pepper M, Jenkins MK. Origins of CD4(+) effector and central memory T cells. Nat Immunol 2011; 12: 467-471.
32. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
33. Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood 2013; 121: 2402-2414.
34. Franki SN, Steward KK, Betting DJ, Kafi K, Yamada RE, Timmerman JM. Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. Blood 2008; 111: 1504-1511.
35. Road JM, Joschi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007; 13: 6419-6428.
36. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+ CD4+ T cells: A common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 5211-5218.
37. Darrasse-Jèze G, Bergot AS, Durgeau A, Billiard F, Salomon BL, Cohen JL et al. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest 2009; 119: 2648-2662.
38. Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Front Immunol 2013; 4: 190.
39. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumorinfiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005; 202: 885-891.